Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
J Exp Clin Cancer Res ; 22(3): 411-8, 2003 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-14582700

RESUMO

Naphthalmustine, 2-[2-[bis-(2-chloroethyl)amino]ethyl]-1H-benz[de]isoquinoline-1,3-dione (Compound 1) has been synthesized as a rationally designed new anticancer agent from N-(2-bromoethyl)naphthalimide. Its chemical alkylating activity exceeded that of nor-HN2 used as standard compound for comparison. Its antitumour efficacy was assessed in vivo in two murine ascites tumours namely Sarcoma-180 (S-180) and Ehrlich ascites carcinoma (EAC) by measuring the increase in median survival times (MST) of drug treated (T) over untreated control (C) mice. The clinical drug cyclophosphamide and the experimental compound mitonafide were used as positive controls for comparison. Compound 1 has displayed substantial and reproducible antitumoural activity in these tumours since very high remission times of treated animals were observed. Significant increase in the life span of mice bearing highly advanced tumour for 10 days before the drug challenge was also noted after its treatment. Its LD50 value was 200 mg/Kg by single i.p. injection. Its toxicity was also assessed in vivo in normal and in S-180 bearing mice by measuring drug-induced changes in hematological parameters, femoral bone marrow and splenic cellularity sequentially on days 9, 15 and 21 following drug treatment at the optimum dose of 12 mg/kg from day 1 to 7. The results indicated that the compound did not adversely affect hematopoiesis. Drug-induced hepatotoxicity and nephrotoxicity were also evaluated on those days but no such toxicities were detected. Naphthalmustine inhibits the synthesis of DNA and RNA in S-180 tumour cells. It was further screened in vitro in 4 different human tumour cell lines but no significant activity was observed in those lines.


Assuntos
Antineoplásicos Alquilantes/síntese química , Antineoplásicos Alquilantes/uso terapêutico , Desenho de Fármacos , Isoquinolinas/síntese química , Isoquinolinas/uso terapêutico , Compostos de Mostarda Nitrogenada/síntese química , Compostos de Mostarda Nitrogenada/uso terapêutico , Animais , Antineoplásicos Alquilantes/efeitos adversos , Antineoplásicos Alquilantes/farmacologia , Divisão Celular/efeitos dos fármacos , Linhagem Celular Tumoral , Humanos , Isoquinolinas/efeitos adversos , Isoquinolinas/farmacologia , Masculino , Camundongos , Estrutura Molecular , Transplante de Neoplasias , Compostos de Mostarda Nitrogenada/efeitos adversos , Compostos de Mostarda Nitrogenada/farmacologia , Taxa de Sobrevida
2.
Planta Med ; 69(2): 164-6, 2003 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-12624825

RESUMO

Two new elemanolides, epivernodalol and lasiopulide, were isolated after chromatographic separation of the alcoholic extract of the dried aerial parts of the Vernonia lasiopus. These elemanolides are new C-10 epimers of the sesquiterpene lactones vernodalol and demethylacroylated vernodalol isolated from other species of Vernonia. Both elemanolides showed in vitro cytotoxicity against human cancer cell lines in culture. This is the first report of isolation and cytotoxic activity of the two elemanolides from V. lasiopus.


Assuntos
Antineoplásicos Fitogênicos/farmacologia , Fitoterapia , Extratos Vegetais/farmacologia , Sesquiterpenos/farmacologia , Vernonia , Antineoplásicos Fitogênicos/administração & dosagem , Antineoplásicos Fitogênicos/química , Antineoplásicos Fitogênicos/uso terapêutico , Células HT29/efeitos dos fármacos , Humanos , Concentração Inibidora 50 , Espectroscopia de Ressonância Magnética , Extratos Vegetais/administração & dosagem , Extratos Vegetais/química , Extratos Vegetais/uso terapêutico , Sesquiterpenos/administração & dosagem , Sesquiterpenos/isolamento & purificação
3.
Acta Pol Pharm ; 60(4): 285-91, 2003.
Artigo em Inglês | MEDLINE | ID: mdl-14714857

RESUMO

Bromonapmustine 4a and chloronapmustine 4b, two new nitrogen mustards of substituted naphthalimides, have been synthesized as mixed-function anticancer compounds from 4-bromo- and 4-chloro-N-(2-hydroxyethyl)-naphthalimide respectively following a three-step process. Their chemical alkylating activity exceeded that of nor-HN2. Their antitumour efficacy were assessed in vivo in two murine ascites tumours, namely Ehrlich ascites carcinoma (EAC) and Sarcoma-180 (S-180) by measuring the increase in median survival times (MST) of drug treated (T) over untreated control (C) mice. Two standard clinical drugs, namely endoxan (cyclophosphamide) and 5-fluorouracil (5-FU) were used as positive controls for comparison. Both of them have displayed substantial and reproducible antitumoural activity in these tumours comparable with 5-FU. These compounds inhibit the synthesis of DNA and RNA in S-180 tumour cells. These were further screened in vitro in 3 different human tumour cell lines but no significant activity was observed in those lines.


Assuntos
Antineoplásicos/síntese química , Imidas/síntese química , Compostos de Mostarda Nitrogenada/síntese química , Antineoplásicos/farmacologia , Antineoplásicos Alquilantes/síntese química , Antineoplásicos Alquilantes/farmacologia , Linhagem Celular Tumoral , Cromatografia Líquida de Alta Pressão , Cromatografia em Camada Fina , DNA de Neoplasias/biossíntese , Desenho de Fármacos , Ensaios de Seleção de Medicamentos Antitumorais , Humanos , Imidas/farmacologia , Compostos de Mostarda Nitrogenada/farmacologia , RNA Neoplásico/biossíntese , Espectrofotometria Infravermelho , Espectrofotometria Ultravioleta , Espectroscopia de Infravermelho com Transformada de Fourier
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...